These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 503634)
1. Dialysis bone disease in childhood: treatment with 25-hydroxycholecalciferol. Luciani JC; Meunier PJ; Dumas R Pediatr Res; 1979 Oct; 13(10):1105-8. PubMed ID: 503634 [TBL] [Abstract][Full Text] [Related]
2. Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure. Witmer G; Margolis A; Fontaine O; Fritsch J; Lenoir G; Broyer M; Balsan S Kidney Int; 1976 Nov; 10(5):395-408. PubMed ID: 794558 [TBL] [Abstract][Full Text] [Related]
3. [Effects of 1 alpha-(OH)D3 on renal osteodystrophy--a 5-year retrospective evaluation]. Kakuhara T; Mizoguchi M; Itoh M; Nagasawa M; Mori T; Ohtsuka K; Kubota M; Minatoguchi T; Ohara K; Yoshida M; Koide H; Ohno J Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):693-704. PubMed ID: 7176180 [No Abstract] [Full Text] [Related]
5. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy. Gotloib L; Mines M; Mazur Y; Sklan D; Garmizo AL; Jancu J; Israeli M; Malul M Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163 [TBL] [Abstract][Full Text] [Related]
6. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy. Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961 [TBL] [Abstract][Full Text] [Related]
7. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease. Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115 [TBL] [Abstract][Full Text] [Related]
8. [Renal osteodystrophy: the importance of 1-alpha-OH-D3]. Berland Y; Olmer M; Grandvuillemin M; Lachaize AM Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385 [TBL] [Abstract][Full Text] [Related]
9. Serum alkaline phosphatase in azotemic and hemodialysis osteodystrophy: a study of isoenzyme patterns, their correlation with bone histology, and their changes in response to treatment with 1alphaOHD3 and 1,25(OH)2D3. Pierides AM; Skillen AW; Ellis HA J Lab Clin Med; 1979 Jun; 93(6):899-909. PubMed ID: 438610 [TBL] [Abstract][Full Text] [Related]
10. Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients. Popovtzer MM; Levi J; Bar-Khayim Y; Shasha SM; Boner G; Bernheim J; Chaimovitz C; Rubinger D; Gafter U; Gazit D Bone; 1992; 13(5):369-77. PubMed ID: 1419378 [TBL] [Abstract][Full Text] [Related]
11. [Treatment with 1-alpha hydroxy vitamin D3 of bone disease in hemodialysis. Therapeutic results and complications]. García de Vinuesa S; Barril G; Luño J; Alles A; Jofré R; Pérez García R; Olivas E; López Gómez JM; Valderrábano F Rev Clin Esp; 1980 Dec; 159(5):317-22. PubMed ID: 7221095 [No Abstract] [Full Text] [Related]
12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V; Torregrosa V Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742 [TBL] [Abstract][Full Text] [Related]
13. 25-hydroxycholecalciferol in the treatment of renal osteodystrophy in haemodialysed patients. Coen G; Taccone-Gallucci M; Bonucci E; Bianchini G; Gallucci G; Lucentini G; Matteucci MC; Picca S; Casciani CU Int J Artif Organs; 1979 Nov; 2(6):278-81. PubMed ID: 511368 [TBL] [Abstract][Full Text] [Related]
14. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients]. Sebert JL; Marie A; Kuntz D; Marie P; Gueris J; Smadja A; Fournier A; Quichaud J Rev Rhum Mal Osteoartic; 1981; 48(7-9):535-41. PubMed ID: 7291931 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of 1 alpha-hydroxyvitamin D3 in children with renal osteodystrophy associated with hemodialysis. Chan JC; Oldham SB; DeLuca HF J Pediatr; 1977 May; 90(5):820-4. PubMed ID: 853343 [TBL] [Abstract][Full Text] [Related]
16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
17. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium. Winney RJ; Bone JM; Anderson TJ; Robson JS Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593 [No Abstract] [Full Text] [Related]
18. [Effect of 1 alpha-hydroxycholecalciferol (1 alpha-OH-D3) and eel calcitonin derivative in experimental renal osteodystrophy]. Minatoguchi T Nihon Jinzo Gakkai Shi; 1982 Oct; 24(10):1157-71. PubMed ID: 7161947 [No Abstract] [Full Text] [Related]
19. Renal osteodystrophy in children on CAPD: a prospective trial of 1-alpha-hydroxycholecalciferol therapy. Watson AR; Kooh SW; Tam CS; Reilly BJ; Balfe JW; Vieth R Child Nephrol Urol; 1988-1989; 9(4):220-7. PubMed ID: 3255485 [TBL] [Abstract][Full Text] [Related]
20. Renal osteodystrophy. Effect of hemodialysis and 1 alpha-hydroxy vitamin D3 on bone lesions and metacarpal bone mass. Andresen J; Nielsen HE; Johannsen A Acta Radiol Diagn (Stockh); 1980; 21(4):541-4. PubMed ID: 7457184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]